Monday, 27 March 2017
Latest news
Main » Aegis Reiterates Buy Rating for Ocera Therapeutics Inc. (OCRX)

Aegis Reiterates Buy Rating for Ocera Therapeutics Inc. (OCRX)

26 January 2017

12/07/2015 - Rodman & Renshaw began new coverage on Sorrento Therapeutics, Inc. giving the company a "buy" rating. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging). Wedbush restated an "outperform" rating and issued a $15.00 price target on shares of Stemline Therapeutics in a research report on Tuesday, November 8th.

3 number of analysts also provided their insight on Orexigen Therapeutics, Inc., where the Average Price Target for the stock is $11.67. They now have a Dollars 20 price target on the stock.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has a mean revenue estimate for the ongoing quarter ending Dec 16 of $5.03M, according to 15 analysts.

11/03/2016 - Deutsche Bank began new coverage on Halozyme Therapeutics, Inc. giving the company a " rating. They set a buy rating and a $10.00 target price for the company.

Hyperion Therapeutics, Inc. had its "hold" rating reiterated by analysts at Needham & Company. Over the one year trading period, the stock has a high price of $127.00 and its low price is recorded at $93.05.

02/01/2016 - Canaccord Genuity began new coverage on Halozyme Therapeutics, Inc. giving the company a " rating. The stock has its Price to Earnings (P/E) ratio of 0 and Forward Price to Earnings ratio of 0.

01/15/2014 - Sorrento Therapeutics, Inc. had its "buy" rating reiterated by analysts at Noble Financial. They now have a Dollars 20 price target on the stock. Finally, William Blair reissued an "outperform" rating and set a $88.00 target price on shares of Sarepta Therapeutics in a report on Sunday, October 2nd.

06/22/2015 - Halozyme Therapeutics, Inc. had its " rating reiterated by analysts at JP Morgan. They now have a Dollars 37 price target on the stock.

06/01/2015 - Halozyme Therapeutics, Inc. had its " rating reiterated by analysts at MLV & Co. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/01/26/stemline-therapeutics-inc-stml-insider-david-gionco-sells-3593-shares-of-stock.html. They now have a Dollars 39 price target on the stock.

07/10/2015 - Sorrento Therapeutics, Inc. had its "buy" rating reiterated by analysts at H.C. Wainwright. They now have a United States dollars 40 price target on the stock. The stock's weekly volatility was 5.46% and the RSI amounts to 41.41.

04/15/2014 - Halozyme Therapeutics, Inc. had its " rating reiterated by analysts at Citic Securities. The firm has a 50-day moving average of $11.94 and a 200-day moving average of $10.43. The stock's market capitalization is 1.51B, it has a 52-week low of 6.96 and a 52-week high of 14.38. 0 shares were traded on Hyperion Therapeutics, Inc.'s last session. The Company is focused on acute and chronic orphan liver diseases. The Company operates in research, development and commercialization of enzymes segment. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101). News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion Therapeutics, Inc. with MarketBeat.com's FREE daily email newsletter.